Galit Frydman, DVM, ScD
President and Chief Science Officer
Dr. Frydman holds positions in the Division of Trauma, Emergency Surgery and Surgical Critical Care at the Massachusetts General Hospital and in the Center for Biomedical Engineering at the Massachusetts Institute of Technology, where she specializes in coagulopathies and immunothrombosis. Dr. Frydman has completed several fellowships at MIT, HMS and MGH, where she developed Coagulo’s platform technology. She has published numerous papers and book chapters on coagulation, platelet physiology, immunothrombosis and stem cell biology. Dr. Frydman earned a ScD in Biological Engineering from MIT, a DVM from the University of Florida, and a BS in Biology from Carnegie Mellon University.
Jarrod Niebloom, JD
Chairman and Chief Executive Officer
Mr. Niebloom was a faculty member at the Harvard Law School, and has advised global corporations, federal and state government officials and other high-profile clients on a range of constitutional and complex legal matters, including antitrust, various aspects of federal justiciability doctrine, preemption and a host of federal statutory and administrative issues. He has worked with litigants and counsel in cases before the U.S. Supreme Court and has authored the forthcoming law treatise, Constitutional Principles, Antitrust Theory. Mr. Niebloom earned a JD from Harvard Law School, and a BA in Quantitative Economics and Political Theory from Tufts University.
Barry Berger, MD, FCAP
Chief Medical Officer
Dr. Berger served as CMO at Exact Sciences Corp. for over 20 years, where he was responsible for key strategic collaborations with academic, research, clinical, political, medical, professional and patient advocacy groups and spearheaded regulatory and reimbursement strategy. Before joining Exact, Dr. Berger was the Chair of Pathology and Laboratory Medicine at Harvard Pilgrim Healthcare, Associate Director of Pathology and Laboratory Medicine at Harvard Community Health Plan and a faculty member in Pathology at Harvard Medical School. Dr. Berger completed his residency in Pathology at Brigham and Women’s Hospital and received his MD from UPenn and his BS in Biology from the University of Miami.
Frank LaDuca, PhD, FAHA
Chief Technology Officer
Dr. LaDuca has 30 years of experience developing and commercializing in vitro diagnostics, including for coagulation testing. Dr. LaDuca previously served as the CSO of Accriva Diagnostics, ITC and PTS as well as the VP of Quality Systems at Siemens Diagnostics and the Senior Director of Global Regulatory & Compliance at Bayer Diagnostics. Dr. LaDuca is the past Chair of the AACC Critical Point-of-Care Division and past Chair of the CLSI for Point-of-Care Testing. Dr. LaDuca completed fellowships at Johns Hopkins Hospital and earned a MS and PhD from SUNY-Buffalo and a BS from SUNY-Albany.
Marcia Zucker, PhD
Head of Regulatory Affairs
Dr. Zucker is an expert in medical diagnostics, specializing in coagulation. Dr. Zucker is a fellow of the AACC, where she has served as Chair of the Critical and Point-of-Care Testing Division, and is a member of the CLSI for Point-of-Care Testing. Previously, Dr. Zucker was the Director of Clinical Research at ITC, where she focused on point-of-care in vitro diagnostics and led teams in clinical, regulatory, marketing, QA and sales as well as risk assessment activities (FMEA) and acting as the “voice of the customer” on new product development. Dr. Zucker earned her PhD in Molecular Biology from Princeton University and her BS in Biology from Rennselaer Polytechnic Institute.
